PURPOSE: The aim of this study was to evaluate the retinal toxicity of high-dose intravitreal etanercept, a U.S. Food and Drug Administration-approved anti-inflammatory drug, in the rabbit model. METHODS: Twenty (20) New Zealand albino rabbits were divided into 5 groups (n=4); eyes in each group were intravitreally injected with one of the following doses of etanercept: 125 microg, 250 microg, 500 microg, 1 mg, or 2.5 mg. One (1) eye in each animal was used for the study dose; the fellow eye was injected with buffered sterile saline as a control. All animals were examined using indirect ophthalmoscopy and slit-lamp biomicroscopy before and after intravitreal injection and at days 1, 7, and 14. Electroretinography (ERG) was performed on all animals before intravitreal injection and 14 days after injection. The animals were euthanized on day 14. Histological preparations of the enucleated eyes were examined with light microscopy for retinal toxicity. RESULTS: Clinical examination, histological evaluation, and ERG results of all 5 groups demonstrated no signs of retinal toxicity. CONCLUSIONS: Intravitreal doses as high as 2.5 mg of etanercept did not cause retinal toxicity. Intravitreal doses of up to 2.5 mg of etanercept may provide a more potent, prolonged effect than the lower doses previously recommended.
PURPOSE: The aim of this study was to evaluate the retinal toxicity of high-dose intravitreal etanercept, a U.S. Food and Drug Administration-approved anti-inflammatory drug, in the rabbit model. METHODS: Twenty (20) New Zealand albino rabbits were divided into 5 groups (n=4); eyes in each group were intravitreally injected with one of the following doses of etanercept: 125 microg, 250 microg, 500 microg, 1 mg, or 2.5 mg. One (1) eye in each animal was used for the study dose; the fellow eye was injected with buffered sterile saline as a control. All animals were examined using indirect ophthalmoscopy and slit-lamp biomicroscopy before and after intravitreal injection and at days 1, 7, and 14. Electroretinography (ERG) was performed on all animals before intravitreal injection and 14 days after injection. The animals were euthanized on day 14. Histological preparations of the enucleated eyes were examined with light microscopy for retinal toxicity. RESULTS: Clinical examination, histological evaluation, and ERG results of all 5 groups demonstrated no signs of retinal toxicity. CONCLUSIONS: Intravitreal doses as high as 2.5 mg of etanercept did not cause retinal toxicity. Intravitreal doses of up to 2.5 mg of etanercept may provide a more potent, prolonged effect than the lower doses previously recommended.
Authors: Isabel Pascual-Camps; Pablo Hernández-Martínez; Laura Monje-Fernández; Rosa Dolz-Marco; Roberto Gallego-Pinazo; Lihteh Wu; J Fernando Arévalo; Manuel Díaz-Llopis Journal: J Ophthalmic Inflamm Infect Date: 2014-10-15
Authors: Zhenying Nie; Gregory D Scott; Patrick D Weis; Asako Itakura; Allison D Fryer; David B Jacoby Journal: Br J Pharmacol Date: 2011-09 Impact factor: 8.739
Authors: Panagiotis G Theodossiadis; Vasilios S Liarakos; Petros P Sfikakis; Alexander Charonis; Georgios Agrogiannis; Nikolaos Kavantzas; Ioannis A Vergados Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-11-04 Impact factor: 3.117
Authors: Roberta P A Manzano; Gholam A Peyman; Petros E Carvounis; Muhamet Kivilcim; Palwasha Khan; Patricia Chevez-Barrios; Walter Takahashi Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-04-15 Impact factor: 3.117
Authors: Kasper D Kristensen; Peter Stoustrup; Annelise Küseler; Thomas K Pedersen; Jens R Nyengaard; Ellen Hauge; Troels Herlin Journal: Pediatr Rheumatol Online J Date: 2009-02-06 Impact factor: 3.054
Authors: Ceren Durmaz Engin; Serap Cilaker Miçili; Osman Yilmaz; Hüsnü Alper Bağriyanik; Bekir Uğur Ergür; Fatoş Önen; Ali Osman Saatci Journal: Turk J Med Sci Date: 2020-06-23 Impact factor: 0.973